KospicyKorean filings in English
Filings / CJ Bioscience

Paid-in Capital Increase (Share Issuance) — Material Event of a Subsidiary

CJ Bioscience · 유상증자결정(종속회사의주요경영사항)

OtherKOSDAQ · 311690 Filed 2026-11-10Korean original on DART

English form view 55% translated

Translated from a fixed dictionaryLeft in Korean (free text, names)Numbers and dates are copied unchanged

Decision on paid-in capital increase (material event of subsidiary)

SubsidiaryEzBiome, Inc.Material management matters report
1. Class and Number of New SharesCommon Shares (shares)185,667
Class Shares (shares)-
2. Par Value per 1 Share (KRW)-
3. Total shares issued before capital increase (shares)Common Shares (shares)99,444
Class Shares (shares)-
4. Purpose of financingFacility funds (KRW)-
Business acquisition funds (KRW)-
Operating funds (KRW)299,623,257
Debt repayment funds (KRW)7,251,639,300
Funds for acquiring other companies' securities (KRW)-
Other funds (KRW)-
5. Capital Increase MethodRights offering to shareholders

[For rights offering to shareholders]

6. Issue Price of New SharesFinal issue priceCommon Shares (KRW)40,671
Class Shares (KRW)-
Expected Issue PriceCommon Shares (KRW)-Scheduled Confirmation Date-
Class Shares (KRW)-Scheduled Confirmation Date-
7. Issue Price Calculation Method-
8. Record Date for New Share Allotment-
9. New Shares Allotted per 1 Share (shares)1.867050
10. ESOP Priority Allotment Ratio (%)-
11. Scheduled Subscription DateEmployee Stock Ownership AssociationStart Date-
End Date-
Existing ShareholdersStart Date-
End Date-
12. Payment date2026-11-23
13. Plan for Forfeited Shares-
14. Dividend Accrual Date of New Shares-
15. Scheduled Delivery Date of New Share Certificates-
16. Lead Manager (If Not Direct Offering)-
17. Transferability of Subscription RightsN/A
18. Board Resolution Date (Decision Date)2026-11-09
- Independent (Outside) Directors* PresentPresent (persons)-
Absent (persons)-
- Auditor (Audit Committee Member Who Is Not an Independent (Outside) Director) PresentPresent
19. Registration Statement RequiredNo
20. Reason for filing exemption, if any해당 종속회사는 해외 비상장법인으로 증권신고서 제출대상에 해당하지 않습니다.
21. Subject to KFTC FilingNo
22. Other Matters Relevant to Investment Decisions- 본 공시는 CJ바이오사이언스(주)가 지분 100%를 소유하고 있는 해외(미국)종속법인 EzBiome, Inc.의 주주배정 유상증자 결정에 관한 사항입니다. - 본 유상증자는 EzBiome, Inc.의 기존 차입금을 상환하고 후속 청산절차를 추진하기 위해 재무구조 개선 목적으로 CJ바이오사이언스(주)가 100% 지분 참여 예정입니다. - 본 건의 6. 신주발행가액은 1주당 미화 $30이며, 증자 금액은 미화 $5,570,010으로 2026-11-10 서울외국환중개 고시 매매기준율(1,355.70KRW/USD)을 적용하여 작성되었고, 환율에 따라 변동될 수 있습니다. - 상기 '8.신주배정기준일',18.이사회결의일(결정일)' 은 발행회사의 미국 기준으로 11월 9일이며,'12. 납입일'은 한국기준일입니다. - 하기 '종속회사에 관한 사항'의 '종속회사의 자산총액'은 발행회사의 2025년 말 개별 재무제표이며, '지배회사의 연결 자산총액'은 2025년 12월말 기준입니다.
※ Related Disclosures-

[Subsidiary information]

Subsidiary nameEzBiome, Inc.EnglishEzBiome, Inc.
- Representative한호윤
- Principal business유전체 분석 등(연구 및 개발업)
- Major subsidiaryN/A
Subsidiary total assets (KRW)599,899,865
Parent's consolidated total assets (KRW)72,337,467,194
% of parent's consolidated total assets0.83